TD ASSET MANAGEMENT INC - HTG MOLECULAR DIAGNOSTICS IN ownership

Quarter-by-quarter ownership
TD ASSET MANAGEMENT INC ownership history of HTG MOLECULAR DIAGNOSTICS IN
ValueSharesWeighting
Q1 2020$21,000
-67.7%
63,664
-30.8%
0.00%
Q4 2019$65,000
+3.2%
92,0640.0%0.00%
Q3 2019$63,000
-61.6%
92,064
-6.9%
0.00%
Q2 2019$164,000
-33.1%
98,864
+0.7%
0.00%
Q1 2019$245,000
+2.9%
98,164
+4.9%
0.00%
Q4 2018$238,000
-49.1%
93,564
+0.9%
0.00%
-100.0%
Q3 2018$468,000
+61.4%
92,764
+4.2%
0.00%
Q2 2018$290,000
-8.8%
89,064
+1.4%
0.00%
Q1 2018$318,00087,8640.00%
Other shareholders
HTG MOLECULAR DIAGNOSTICS IN shareholders Q3 2023
NameSharesValueWeighting ↓
Novo Holdings A/S 1,280,185$9,755,0001.01%
Cormorant Asset Management, LP 201,000$1,532,0000.24%
PUTNAM INVESTMENTS LLC 575,692$4,386,0000.01%
Alyeska Investment Group, L.P. 114,113$870,0000.01%
VANGUARD GROUP INC 4,355,424$131,473,0000.01%
BLACKROCK ADVISORS LLC 463,200$3,530,0000.00%
OCONNOR, A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS (LLC) 26,100$199,000,0000.00%
Ironwood Financial, llc 870$7,0000.00%
PANAGORA ASSET MANAGEMENT INC 24,293$185,0000.00%
Sonora Investment Management, LLC 500$3,0000.00%
View complete list of HTG MOLECULAR DIAGNOSTICS IN shareholders